Source: Annual Congress 2007 - Clinical aspects of interstitial lung disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Sobiecka, U. Demkow, M. Filewska, D. Giedronowicz, J. Kus (Warsaw, Poland). Safety of sputum induction (SI) in interstitial lung disease (ILD). Eur Respir J 2007; 30: Suppl. 51, 4493

Member's Comments

No comment yet.

Related content which might interest you: Diagnostic value of induced sputum (IS) in interstitial lung disease (ILD) Source: Annual Congress 2007 - Clinical aspects of interstitial lung disease Year: 2007 Diagnostic value of CD4/CD8 ratio in induced sputum (IS) in interstitial lung disease (ILD) Source: Annual Congress 2004 - Pathobiological and clinical investigations in interstitial lung diseases Year: 2004 Nasal high-Flow (NHF) improves ventilation in patients with interstitial lung disease (ILD) Source: International Congress 2019 – Hot topics in noninvasive ventilation Year: 2019 Alveolar lymphocytes (AL) apoptosis in interstitial lung diseases (ILD). Increased AL apoptosis rate in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis Year: 2009 UIP-like or NSIP pattern in interstitial lung disease patients (ILD), following by ‘connective tissue disease ‘(CTD) Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012 Pulmonary rehabilitation (PR) outcomes in chronic obstructive pulmonary disease (COPD) compared with interstitial lung disease (ILD) Source: Annual Congress 2011 - Pulmonary rehabilitation: looking at alternative approaches and alternative populations beyond COPD Year: 2011 Induced sputum (IS) in patients with interstitial lung disease (ILD) – comparison with bronchoalveolar lavage (BAL) Source: Annual Congress 2007 - Clinical aspects of interstitial lung disease Year: 2007 Is it possible to predict the outcome of the whole lung lavage (WLL) in pulmonary alveolar proteinosis (PAP)? Source: International Congress 2015 – IIPs: orphan Year: 2015 Pulmonary rehabilitation (PR) exercise tolerance improvement: Differences between interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2013 –Exercise, physiotherapy techniques and assessment in different chronic conditions Year: 2013 Elevated apoptosis rate of alveolar lymphocytes (AL) in idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonitis (NSIP) – strong positive correlation with bronchoalvoelar lavage (BAL) neutrophil count. Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis Year: 2020 mRNA expression of YY1, TNF-α a TGF-β in lung samples gained by transbronchial biopsies (TBB) in patients with different interstitial lung diseases (ILDs) Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP) Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Outcome differences between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD) - data from the EXCITING registry Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018 Antisynthetase syndrome (AS) in patients with diffuse interstitial lung disease (ILD) Source: International Congress 2015 – Connective tissue disorders Year: 2015 The Gender-Age-Physiology (GAP) Index enhanced with KL-6 serum level for predicting disease progression in interstitial lung diseases (ILD). Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 The importance of pulmonary mineralogic analysis (PMA) in interstitial lung disease (ILD). A retrospective study of 226 samples from 2005 to 2011 Source: Annual Congress 2013 –Occupational respiratory diseases: asthma, silicosis and asbestosis Year: 2013 Effects of pulmonary rehabilitation in patients with interstitial lung disease (ILD) Source: Annual Congress 2009 - New treatment and outcome measures for pulmonary rehabilitation Year: 2009 Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 A gene network to predict the clinical response to whole lung lavage (WLL), in pulmonary alveolar proteinosis (PAP). Source: International Congress 2017 – Novel and old entities Year: 2017